Ibrutinib combination therapy in an exciting therapeutic area with great potential. Many recent and ongoing studies are seeking to identify the optimal ibrutinib combinations for the treatment of chronic lymphocytic leukemia (CLL). Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, George Follows, BMBCh, PhD, FRCP, FRCPath, of Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, highlights data that was presented at the meeting which evaluated ibrutinib combination therapy for CLL, including that with venetoclax and anti-CD20 antibodies.
Ibrutinib combination therapy in CLL: overview of the data so far
